Melanie A Hundt1, Yanhong Deng2, Maria M Ciarleglio2, Michael H Nathanson1,3, Joseph K Lim1,3. 1. Department of Medicine, Yale School of Medicine, New Haven, CT. 2. Yale Center for Analytical Sciences, Yale School of Public Health, New Haven, CT. 3. Yale Liver Center and Section of Digestive Diseases, Yale School of Medicine, New Haven, CT.
Abstract
BACKGROUND AND AIMS: The coronavirus-19 disease (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 virus, is associated with significant morbidity and mortality attributable to pneumonia, acute respiratory distress syndrome, and multiorgan failure. Liver injury has been reported as a nonpulmonary manifestation of COVID-19, but characterization of liver test abnormalities and their association with clinical outcomes is incomplete. APPROACH AND RESULTS: We conducted a retrospective cohort study of 1,827 patients with confirmed COVID-19 who were hospitalized within the Yale-New Haven Health System between March 14, 2020 and April 23, 2020. Clinical characteristics, liver tests (aspartate aminotransferase [AST], alanine aminotransferase [ALT], alkaline phosphatase [ALP], total bilirubin [TBIL], and albumin) at three time points (preinfection baseline, admission, and peak hospitalization), and hospitalization outcomes (severe COVID-19, intensive care unit [ICU] admission, mechanical ventilation, and death) were analyzed. Abnormal liver tests were commonly observed in hospitalized patients with COVID-19, both at admission (AST 66.9%, ALT 41.6%, ALP 13.5%, and TBIL 4.3%) and peak hospitalization (AST 83.4%, ALT 61.6%, ALP 22.7%, and TBIL 16.1%). Most patients with abnormal liver tests at admission had minimal elevations 1-2× the upper limit of normal (ULN; AST 63.7%, ALT 63.5%, ALP 80.0%, and TBIL 75.7%). A significant proportion of these patients had abnormal liver tests prehospitalization (AST 25.9%, ALT 38.0%, ALP 56.8%, and TBIL 44.4%). Multivariate analysis revealed an association between abnormal liver tests and severe COVID-19, including ICU admission, mechanical ventilation, and death; associations with age, male sex, body mass index, and diabetes mellitus were also observed. Medications used in COVID-19 treatment (lopinavir/ritonavir, hydroxychloroquine, remdesivir, and tocilizumab) were associated with peak hospitalization liver transaminase elevations >5× ULN. CONCLUSIONS: Abnormal liver tests occur in most hospitalized patients with COVID-19 and may be associated with poorer clinical outcomes.
BACKGROUND AND AIMS: The coronavirus-19 disease (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 virus, is associated with significant morbidity and mortality attributable to pneumonia, acute respiratory distress syndrome, and multiorgan failure. Liver injury has been reported as a nonpulmonary manifestation of COVID-19, but characterization of liver test abnormalities and their association with clinical outcomes is incomplete. APPROACH AND RESULTS: We conducted a retrospective cohort study of 1,827 patients with confirmed COVID-19 who were hospitalized within the Yale-New Haven Health System between March 14, 2020 and April 23, 2020. Clinical characteristics, liver tests (aspartate aminotransferase [AST], alanine aminotransferase [ALT], alkaline phosphatase [ALP], total bilirubin [TBIL], and albumin) at three time points (preinfection baseline, admission, and peak hospitalization), and hospitalization outcomes (severe COVID-19, intensive care unit [ICU] admission, mechanical ventilation, and death) were analyzed. Abnormal liver tests were commonly observed in hospitalized patients with COVID-19, both at admission (AST 66.9%, ALT 41.6%, ALP 13.5%, and TBIL 4.3%) and peak hospitalization (AST 83.4%, ALT 61.6%, ALP 22.7%, and TBIL 16.1%). Most patients with abnormal liver tests at admission had minimal elevations 1-2× the upper limit of normal (ULN; AST 63.7%, ALT 63.5%, ALP 80.0%, and TBIL 75.7%). A significant proportion of these patients had abnormal liver tests prehospitalization (AST 25.9%, ALT 38.0%, ALP 56.8%, and TBIL 44.4%). Multivariate analysis revealed an association between abnormal liver tests and severe COVID-19, including ICU admission, mechanical ventilation, and death; associations with age, male sex, body mass index, and diabetes mellitus were also observed. Medications used in COVID-19 treatment (lopinavir/ritonavir, hydroxychloroquine, remdesivir, and tocilizumab) were associated with peak hospitalization liver transaminase elevations >5× ULN. CONCLUSIONS: Abnormal liver tests occur in most hospitalized patients with COVID-19 and may be associated with poorer clinical outcomes.
Authors: Gong Feng; Kenneth I Zheng; Qin-Qin Yan; Rafael S Rios; Giovanni Targher; Christopher D Byrne; Sven Van Poucke; Wen-Yue Liu; Ming-Hua Zheng Journal: J Clin Transl Hepatol Date: 2020-03-30
Authors: Kishan P Patel; Puja A Patel; Rama R Vunnam; Alexander T Hewlett; Rohit Jain; Ran Jing; Srinivas R Vunnam Journal: J Clin Virol Date: 2020-04-29 Impact factor: 3.168
Authors: Tingyan Wang; David A Smith; Cori Campbell; Eleanor Barnes; Philippa C Matthews; Steve Harris; Hizni Salih; Kinga A Várnai; Kerrie Woods; Theresa Noble; Oliver Freeman; Zuzana Moysova; Thomas Marjot; Gwilym J Webb; Jim Davies Journal: Hepatol Commun Date: 2021-07-10
Authors: Isabel Campos-Varela; Ares Villagrasa; Macarena Simon-Talero; Mar Riveiro-Barciela; Meritxell Ventura-Cots; Lara Aguilera-Castro; Patricia Alvarez-Lopez; Emilie A Nordahl; Adrian Anton; Juan Bañares; Claudia Barber; Ana Barreira-Diaz; Betina Biagetti; Laura Camps-Relats; Andrea Ciudin; Raul Cocera; Cristina Dopazo; Andrea Fernandez; Cesar Jimenez; Maria M Jimenez; Mariona Jofra; Clara Gil; Concepción Gomez-Gavara; Danila Guanozzi; Jorge A Guevara; Beatriz Lobo; Carolina Malagelada; Joan Martinez-Camprecios; Luis Mayorga; Enric Miret; Elizabeth Pando; Ana Pérez-Lopez; Marc Pigrau; Alba Prio; Jesus M Rivera-Esteban; Alba Romero; Stephanie Tasayco; Judit Vidal-Gonzalez; Laura Vidal; Beatriz Minguez; Salvador Augustin; Joan Genesca Journal: Therap Adv Gastroenterol Date: 2021-05-30 Impact factor: 4.409
Authors: Annachiara Rosa; Valerie E Pye; Carl Graham; Luke Muir; Jeffrey Seow; Kevin W Ng; Nicola J Cook; Chloe Rees-Spear; Eleanor Parker; Mariana Silva Dos Santos; Carolina Rosadas; Alberto Susana; Hefin Rhys; Andrea Nans; Laura Masino; Chloe Roustan; Evangelos Christodoulou; Rachel Ulferts; Antoni G Wrobel; Charlotte-Eve Short; Michael Fertleman; Rogier W Sanders; Judith Heaney; Moira Spyer; Svend Kjær; Andy Riddell; Michael H Malim; Rupert Beale; James I MacRae; Graham P Taylor; Eleni Nastouli; Marit J van Gils; Peter B Rosenthal; Massimo Pizzato; Myra O McClure; Richard S Tedder; George Kassiotis; Laura E McCoy; Katie J Doores; Peter Cherepanov Journal: Sci Adv Date: 2021-05-28 Impact factor: 14.136
Authors: Grace Lai-Hung Wong; Terry Cheuk-Fung Yip; Vincent Wai-Sun Wong; Yee-Kit Tse; David Shu-Cheong Hui; Shui-Shan Lee; Eng-Kiong Yeoh; Henry Lik-Yuen Chan; Grace Chung-Yan Lui Journal: Open Forum Infect Dis Date: 2021-04-23 Impact factor: 3.835
Authors: J M Plasencia-Martínez; À Rovira; P Caro Domínguez; I Barber; E García-Garrigós; J J Arenas-Jiménez Journal: Radiologia (Engl Ed) Date: 2021-05-19